Arlington, TX, United States of America

Huagang Chen

This inventor holds 9 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Alcon, Inc., Novartis Ag. Active years: 2003-2012.

USPTO Granted Patents = 9 

% Patents Active = 44.4


 

Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 51(Granted Patents)


Location History:

  • Irving, TX (US) (2003 - 2010)
  • Arlington, TX (US) (2007 - 2012)

Company Filing History:


Years Active: 2003-2012

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Innovations by Huagang Chen in Ophthalmic Compositions

Introduction

Huagang Chen is a notable inventor based in Arlington, TX, who has made significant contributions to the field of ophthalmic compositions. With a total of nine patents to his name, his work focuses on enhancing the effectiveness of artificial tears and ophthalmic drug delivery systems.

Latest Patents

Among his latest patents, Huagang Chen has developed ophthalmic compositions that contain a synergistic combination of two polymers. These compositions are designed for use as artificial tears or as vehicles for ophthalmic drugs. The unique combination of polymers results in a synergistic effect on viscosity, improving the performance of these compositions in clinical applications.

Career Highlights

Throughout his career, Huagang Chen has worked with prominent companies in the pharmaceutical and healthcare sectors. Notably, he has been associated with Alcon, Inc. and Novartis AG, where he has contributed to the development of innovative ophthalmic solutions.

Collaborations

Huagang Chen has collaborated with various professionals in his field, including Masood A Chowhan, to further advance his research and innovations.

Conclusion

Huagang Chen's work in ophthalmic compositions showcases his dedication to improving eye care through innovative solutions. His patents reflect a commitment to enhancing the quality of life for individuals requiring ophthalmic treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…